M&A Deal Summary

Aralez Pharmaceuticals Acquires AstraZeneca - Toprol-XL

On October 4, 2016, Aralez Pharmaceuticals acquired healthcare services company AstraZeneca - Toprol-XL from AstraZeneca for 175M USD

Acquisition Highlights
  • This is Aralez Pharmaceuticals’ 1st transaction in the Healthcare Services sector.
  • This is Aralez Pharmaceuticals’ largest (disclosed) transaction.
  • This is Aralez Pharmaceuticals’ 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2016-10-04
Target AstraZeneca - Toprol-XL
Sector Healthcare Services
Buyer(s) Aralez Pharmaceuticals
Sellers(s) AstraZeneca
Deal Type Divestiture
Deal Value 175M USD

Target

AstraZeneca - Toprol-XL

London, United Kingdom
AstraZeneca Plc - Toprol-XL is a provider of treatment of high blood pressure. By lowering blood pressure, Toprol-XL may lower the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Toprol-XL is also indicated for the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance and for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, Toprol-XL decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aralez Pharmaceuticals

Milton, Ontario, Canada
Category Company
Founded 2015
Sector Life Science
Employees164
Revenue 106M USD (2017)
DESCRIPTION

Aralez Pharmaceuticals is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while focusing on creating shareholder value by acquiring, developing, and commercializing products primarily in cardiovascular, pain, and other specialty areas. Aralez Pharmaceuticals was founded in 2015 and is based in Mississauga, Canada.

DEAL STATS #
Overall 3 of 3
Sector (Healthcare Services) 1 of 1
Type (Divestiture) 1 of 1
Country (United Kingdom) 1 of 1
Year (2016) 3 of 3
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-02-05 POZEN

Chapel Hill, North Carolina, United States

POZEN, Inc. is a pharmaceutical company.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-08-10 Aralez Pharmaceuticals - VIMOVO Royalties

Milton, Ontario, Canada

Aralez Pharmaceuticals, Inc. - VIMOVO Royalties is a provider of biotechnological services in Milton, Canada.

Sell $110M

Seller(S) 1

SELLER

AstraZeneca

Cambridge, United Kingdom
Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 45.8B USD (2023)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 8 of 11
Sector (Healthcare Services) 1 of 1
Type (Divestiture) 8 of 11
Country (United Kingdom) 3 of 5
Year (2016) 2 of 2
Size (of disclosed) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-24 AstraZeneca - Small Molecule Anti-Infective Business

London, United Kingdom

AstraZeneca - Small Molecule Anti-Infective Business includes the commercialization and development rights to the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™ (meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL.

Sell $550M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-05-27 AstraZeneca - Seroquel and Seroquel XR

London, United Kingdom

AstraZeneca Plc - Seroquel and Seroquel XR is an anti-psychotic medicines with antidepressant properties.

Sell -
Mergr

Product

Company

Legal